Chronic recurrent angioedema is when the condition returns over a long period of time
The project described was supported in part by an Institutional Development Award (IDeA) from the NIGMS of the National Institutes of Health under Grant # 5P20GM103427 2:00 - BASELINE SURVEY OF HONEY BEE PATHOGENS IN APIS MELLIFERA COLONIES ON MO'OREA, FRENCH POLYNESIA USING DIGITAL DROPLET PCR Alexa Kozlak Creighton University Honey bee pathogens are globally widespread and contribute to colony losses
Ingredients: Purified Water (Aqua), Hyaluronic Acid (Sodium Hyaluronate), Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Glycerin, Butylene Glycol, Carbomer, Polysorbate 20, Organic Cocos Nucifera (Coconut) Oil, GHK-Cu (Copper Tripeptide-1), Organic Simmondsia Chinensis (Jojoba) Seed Oil, Citrus Aurantium Dulcis (Orange) Peel Extract, Organic Camellia Sinensis (Green Tea) Leaf Extract, Methylene Blue, Phenoxyethanol
doi: 10.1176/appi.ajp.2018.18040369
What's New: July 2026 Update TRIUMPH-4 confirmed: 28.7% weight loss at 68 weeks in 445 participants topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients with BMI 35 reached 30.3% average weight loss no plateau observed TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Efficacy Summary Across All Completed Trials Phase 2: The Foundation (2023) The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
